Clinical trials: Metformin, completed
Diabetes Mellitus, Type 2
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or without microalbuminuria with dapagliflozin or metformin for 4 months.
- Trial name
- Hyper (NCT02911792)
- Testing
- Dapagliflozin, Metformin, Glipizide 5 MG
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Non-Insulin-Dependent
Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c [HbA1c]…
- Trial name
- NCT00545584
- Testing
- sitagliptin phosphate, Comparator: Diet, Comparator: Physical Activity
- Volunteers
- 1,512 people
- Sponsor
- Merck Sharp & Dohme LLC
Fed Conditions
Bioequivalence Study to Compare Metformin / Vildagliptin Versus Galvumet®
The aim of this study is to assess bioequivalence between a single oral dose from the test product Metformin / Vildagliptin tablets (1000 mg as metformin hydrochloride / 50 mg as vildagliptin) manufactured by Pharmaceutical Arab…
- Trial name
- NCT06073600
- Testing
- Metformin / Vildagliptin Reference Film Coated Tablets (1000 mg / 50 mg) (Galvumet®), Metformin / Vildagliptin Test Film Coated Tablets (1000 mg / 50 mg)
- Where
- Tunisia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Reseach Laboratory of Clinical and Experimental Pharmacology
PCOS
Comparing the Effects of Oral Contraceptive Pills Versus Metformin
To determine the effect of Oral Contraceptive Pills (OCP) verses Metformin verses OCP and Metformin on the prevalence of Metabolic Syndrome (MetS) and its components in overweight/obese women with Polycystic Ovary Syndrome…
- Trial name
- COMET-PCOS (NCT03229057)
- Testing
- OCP + Metformin
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Anuja Dokras
PreDiabetes, Diabetes Mellitus
Diabetes Risk Education and Communication Trial
A large body of research has demonstrated that intensive lifestyle interventions and metformin are effective treatments to prevent or delay diabetes among high-risk adults, yet neither treatment is routinely used in practice.
- Conditions
- PreDiabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Body Weight
- Trial name
- DiRECT (NCT03283657)
- Testing
- DiRECT, Usual care (UC)
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- NCT03842267
- Testing
- Gemigliptin 50mg
- Where
- South Korea
- Volunteers
- 315 people
- Sponsor
- LG Chem
Diabetes Mellitus Type 2
Study to Identify Adequate Biomarker to Detect Vitamin B12 Deficiency in Type 2 Diabetic Patients Treated With Metformin
In this study we compare the vitamin B12 status by measuring serum vitamin B12 and holotranscobalamin in type 2 diabetic patients with and without metformin treatment.
- Trial name
- NCT02111967
- Testing
- Questionnaire administration, Laboratory biomarker analysis
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Basel, Switzerland
Type 2 Diabetes, Obese Diabetics
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
This study explores the long-term effects of dapagliflozin and empagliflozin on CYP8B1 gene expression and a range of metabolic, oxidative, and inflammatory biomarkers in obese patients with Type 2 Diabetes Mellitus (T2DM).
- Conditions
- Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)
- Trial name
- CYP8B1-SGLT2-T (NCT07120828)
- Testing
- Empagliflozin (oral), Dapagliflozin (DAPA), Metfomin
- Where
- Iraq
- Volunteers
- 260 people
- Sponsor
- Erbil Polytechnic University
Healthy Participants
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult…
- Trial name
- NCT06416800
- Testing
- Digoxin, Rosuvastatin, Metformin
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Frailty
Metformin for Preventing Frailty in High-risk Older Adults
Frailty is a geriatric syndrome which leads to poor health outcomes in older adults, such as falls, disability, hospitalization, institutionalization, and death. Due to the dramatic growth in the U.S.
- Trial name
- NCT02570672
- Testing
- Metformin
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
Study B1621019 will assess efficacy and safety of two different dosing regimens of an investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients with type 2 diabetes
- Trial name
- NCT01933672
- Testing
- PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Coronary Artery Disease
Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery
Background Endothelial dysfunction is one of the early events in atherosclerotic plaque development. It is characterized by an increased ratio of substances with vasoconstrictive, pro-thrombotic, and proliferative properties over…
- Conditions
- Diabetes Mellitus, Type 2, Coronary Artery Disease, Carotid Artery Diseases
- Trial name
- ADDENDA (NCT02919345)
- Testing
- Dapagliflozin 10 mg, Glibenclamide 5 mg
- Where
- Brazil
- Volunteers
- 98 people
- Sponsor
- University of Campinas, Brazil
Type 2 Diabetes Mellitus (T2DM)
Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
To assess the relative bioavailability of dapagliflozin and metformin from the two FDC formulations, comprised of 10 mg dapagliflozin and 1000 mg metformin XR, relative to coadministration of a dapagliflozin 10 mg tablet and 2 x…
- Trial name
- NCT01002807
- Testing
- Dapagliflozin, Metformin XR, Glucophage
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study
The purpose of the ROSITEL study is to assess the effects of rosiglitazone, as compared to standard oral therapies for diabetes (metformin/sulfonylurea), on inflammatory markers and adipokine levels in diabetic patients using an…
- Trial name
- NCT00486187
- Testing
- rosiglitazone, metformin or sulfonylurea
- Where
- Canada
- Volunteers
- 103 people
- Sponsor
- Dr. Milan Gupta
Advanced Cancers
Lapatinib With Sirolimus or Metformin
The goal of this clinical research study is to find the highest tolerable dose of 2 different combinations of drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01087983
- Testing
- Lapatinib, Sirolimus, Metformin
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- M.D. Anderson Cancer Center
Healthy
Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates
This study consisted of 2 parts: Part 1 and 2. The purpose of this study was to evaluate the pharmacokinetic, safety and tolerability of multiple doses of evobrutinib on single doses of digoxin, metformin and rosuvastatin in…
- Trial name
- NCT05064488
- Testing
- Evobrutinib (45mg), Digoxin (0.25mg), Metformin (10mg)
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Glucose Metabolism Disorders, Diabetes Mellitus, Type 2
Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
The primary aim of this study is to assess the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+Dipeptidyl peptidase 4…
- Conditions
- Glucose Metabolism Disorders, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Empagliflozin
- Trial name
- NCT06145360
- Testing
- Empagliflozin 10 MG, Insulin+Metformin+DPP4 inhibitor (DPP4I)
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- SINA Health Education and Welfare Trust
Cardiovascular Disease
Effects of Lipemia and Metformin on Endothelial Function
Eating a diet high in fat contributes to the development of atherosclerosis (hardening of the arteries). Acute fat consumption increases levels of fat in the blood and temporarily reduces the ability of blood vessel to dilate…
- Trial name
- NCT01037660
- Testing
- Metformin
- Where
- United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Boston University
Rectal Cancer, Metformin
DataBase for Analysis of Rectal Cancer Oncological Results
The data will be obtained from 10 tertiary centers located in Poland (Cracow - coordinating center, Warsaw - 3 centers, Sosnowiec, Szczecin, Bydgoszcz, Lublin, Gdansk, Poznan) and 5 foreign centers.
- Conditions
- Rectal Cancer, Metformin, Overall Survival, Lymph Node Metastases
- Trial name
- BARO (NCT04947020)
- Testing
- Metformin
- Where
- Poland
- Volunteers
- 2,443 people
- Sponsor
- Jagiellonian University
Type 2 Diabetes
Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control
Obtain Continuous Glucose Monitoring (CGM) data from individuals taking exenatide LAR, sitagliptin, or pioglitazone. The CGM measurements collected will help determine the characteristics of glucose control prior to treatment and…
- Trial name
- NCT00806520
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- HealthPartners Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.